Metro-Minnesota Community Clinical Oncology Program

大都会明尼苏达州社区临床肿瘤学项目（MMCCOP）代表了九家医院的联盟， 通过其NCI资助的社区医院肿瘤学项目（“CHOP”）和运营CCOP， 管理癌症病人的方法，并有一个既定的机制，以识别，进入和跟踪病人 治疗和癌症预防和控制协议。该联合会有一个全社区的计算机化数据管理系统， 能够进行前瞻性数据收集的系统。社区提供PPO，HMO和商业医疗保健计划，所有 在这九家联合医院中有代表。这九家医院平均每年有9700个新的分析 每年的癌症患者100名核心和待定的新研究者，代表医学和放射肿瘤学，血液学， 泌尿科、妇科肿瘤科、神经科、耳鼻喉科、家庭诊所、普通外科和专科外科医生， 关于癌症方案制定和方案制定的现行方案结构和运作。在最近一 在NCI-funded grant year（6/03-5/04），880名患者/参与者（192.3治疗积分+299.6癌症控制积分）累计到 NCI批准的治疗和癌症预防和控制研究。MMCCOP打算维持一个区域范围的社区 及医院联盟，为市民提供预防，控制及治疗癌症的最新进展。 这将通过进一步扩大CCOP到已建立的外联社区来实现;与医院合作， 基金会、保险公司和综合服务网络，为参加 临床试验;增加初级保健医生的参与;提供专业知识，资源和庞大的人口基础， 通过与NCI，CTSU，ECOG，GOG的合作，开发，实施和评估临床癌症治疗和对照试验， MD安德森、NSABP、RTOG、URCC和与NCCTG的试点项目;改进和扩展当前的MMCCOP数据 管理和通信系统，以增加调查人员参与权责发生制方案的人数和水平 业务和研究基地活动;实施新战略，改善少数群体和得不到充分服务的群体的机会和参与 提高专业人士和非专业人士对CCOP的认识以及临床癌症试验的益处。基于 过去的经验，癌症控制和预防试验的可用性，多个研究基地和成功的癌症控制 实施模型，MMCCOP研究者打算招募1040人（581.6学分/413.5新+ 168.1随访） 在第一年，将患者/参与者纳入NCI批准的癌症治疗和对照研究，目标是持续 超过了NCI对这两类研究的要求。审查人员当时认为，先前的MMCCOP申请 “过于乐观”，但被超越了。第一年的资助目标仍然是乐观的，但考虑到专业知识， 该小组的成员、可用的协议、已建立的系统以及医生和医院的大力支持。

The Metro-Minnesota Community Clinical Oncology Program(MMCCOP) represents a consortium of nine hospitals which, through its NCI-funded Community Hospital Oncology Program ("CHOP") and operational CCOP, has developed acommon approach to the management of cancer patients and has an established mechanism for identifying, entering and following patients on treatment and cancer prevention and control protocols. The consortium has a community-wide computerized data management system capable of prospective data collection. The community offers PPOs, HMOs and commercial healthcare programs, all of which are represented among these nine consortium hospitals. Together, the nine hospitals see an averageof 9700 new analytic cancer patients per year. The 100 core and pending new investigators, representing medical and radiation oncology, hematology, urology, gynecologic oncology, neurology, ENT, family practice, general and specialty surgeons, have worked extensively together on cancer program development and protocol development of the current program structure and operation. During the most recent NCI-funded grant year (6/03-5/04), 880 patients/participants (192.3 treatmentcredits+299.6 cancer control credits) were accrued to NCI-approved treatment and cancer prevention and control studies. The MMCCOP intends to sustain a region wide community and hospital consortium, which provides the community with the most recent advances in cancer prevention, control and treatment. This will be accomplished through further expansion of the CCOP into established outreach communities; work withhospitals, foundations, insurers and Integrated Service Networks (ISNs) to develop funding and reimbursement support for participation in clinical trials; increased involvement of primary care physicians; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, CTSU, ECOG, GOG, MD Anderson, NSABP, RTOG, URCC and pilot project with the NCCTG; improve and expand the current MMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities; implement new strategies to improve access and participation of minority and underserved groups; and increase the professionaland lay community awareness of the CCOP and benefits of clinical cancer trials. Based upon past experience, the availability of cancer control and prevention trials, multiple research bases and successful cancer control implementation models, MMCCOP investigators intend to enroll 1040 (581.6 credits/413.5 new + 168.1 follow-up) patients/participants onto NCI-approved cancer treatment and control studies during the first year, with the goal of continually exceeding the NCI requirements for both types of studies. Prior MMCCOP applications were viewed by reviewers at that time as "overly optimistic",but were exceeded. The goal for the first year of this grant is again optimistic, but realisticgiventhe expertise of the group, available protocols, the established systems and strong support of the physiciansandhospitals.